PL2146749T3 - Znaczone peptydy wiążące HGF przydatne do obrazowania - Google Patents

Znaczone peptydy wiążące HGF przydatne do obrazowania

Info

Publication number
PL2146749T3
PL2146749T3 PL08750628T PL08750628T PL2146749T3 PL 2146749 T3 PL2146749 T3 PL 2146749T3 PL 08750628 T PL08750628 T PL 08750628T PL 08750628 T PL08750628 T PL 08750628T PL 2146749 T3 PL2146749 T3 PL 2146749T3
Authority
PL
Poland
Prior art keywords
imaging
labelled
binding peptides
hgf binding
monitoring
Prior art date
Application number
PL08750628T
Other languages
English (en)
Inventor
Edvin Wilhelm Johannesen
Alan Cuthbertson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of PL2146749T3 publication Critical patent/PL2146749T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
PL08750628T 2007-05-16 2008-05-16 Znaczone peptydy wiążące HGF przydatne do obrazowania PL2146749T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging
EP08750628A EP2146749B1 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (1)

Publication Number Publication Date
PL2146749T3 true PL2146749T3 (pl) 2012-09-28

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08750628T PL2146749T3 (pl) 2007-05-16 2008-05-16 Znaczone peptydy wiążące HGF przydatne do obrazowania

Country Status (17)

Country Link
US (1) US8529874B2 (pl)
EP (1) EP2146749B1 (pl)
JP (1) JP2010526859A (pl)
KR (2) KR20150017387A (pl)
CN (1) CN101848734B (pl)
AT (1) ATE551073T1 (pl)
AU (1) AU2008249821B2 (pl)
BR (1) BRPI0811210B1 (pl)
CA (1) CA2685553C (pl)
ES (1) ES2385066T3 (pl)
IL (1) IL201778A0 (pl)
MX (1) MX2009012386A (pl)
NZ (1) NZ581160A (pl)
PL (1) PL2146749T3 (pl)
RU (2) RU2473361C9 (pl)
WO (1) WO2008139207A2 (pl)
ZA (1) ZA200908016B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581161A (en) * 2007-05-16 2012-06-29 Ge Healthcare As Optical imaging agents
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
US20130095040A1 (en) * 2010-06-29 2013-04-18 Ge Healthcare As Dye compositions and dye syntheses
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
US20120088262A1 (en) * 2010-10-06 2012-04-12 Millipore Corporation Cyanine compounds, conjugates and method of use
EP2680889B1 (en) 2011-03-01 2019-06-19 GE Healthcare Limited Radiolabelled octreotate analogues as pet tracers
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10046068B2 (en) * 2013-03-15 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484218A1 (en) 2002-05-10 2004-05-13 Ratnaker B. Mujumdar Chiral indole intermediates and their fluorescent cyanine dyes containing functional groups
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
US7510699B2 (en) * 2003-02-19 2009-03-31 Sicel Technologies, Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
CA2517939C (en) * 2003-03-03 2015-11-24 Dyax Corp. Peptides that specifically bind hgf receptor (cmet) and uses thereof
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US7750163B2 (en) * 2003-10-31 2010-07-06 GE Healthcare U.K. Limited Cyanine dye labelling reagents
WO2005044313A2 (en) 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
JP5057994B2 (ja) * 2005-01-06 2012-10-24 ジーイー・ヘルスケア・アクスイェ・セルスカプ 光学イメージング
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
ATE502048T1 (de) 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
NO20053354D0 (no) 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
CN101848734A (zh) 2010-09-29
EP2146749B1 (en) 2012-03-28
KR20150017387A (ko) 2015-02-16
AU2008249821A1 (en) 2008-11-20
US20100150843A1 (en) 2010-06-17
IL201778A0 (en) 2010-06-16
ES2385066T3 (es) 2012-07-17
ZA200908016B (en) 2012-04-25
RU2473361C9 (ru) 2013-06-20
ATE551073T1 (de) 2012-04-15
US8529874B2 (en) 2013-09-10
BRPI0811210B1 (pt) 2021-11-09
JP2010526859A (ja) 2010-08-05
KR101578225B1 (ko) 2015-12-17
BRPI0811210A2 (pt) 2014-11-11
NZ581160A (en) 2012-05-25
AU2008249821B2 (en) 2013-08-22
RU2473361C2 (ru) 2013-01-27
CA2685553A1 (en) 2008-11-20
WO2008139207A3 (en) 2009-02-26
KR20100016543A (ko) 2010-02-12
CN101848734B (zh) 2013-08-28
RU2475266C2 (ru) 2013-02-20
CA2685553C (en) 2017-03-28
RU2009140478A (ru) 2011-06-27
RU2009140475A (ru) 2011-06-27
MX2009012386A (es) 2009-12-03
WO2008139207A2 (en) 2008-11-20
EP2146749A2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
ZA200908016B (en) Labelled hgf binding peptides for imaging
GB0718967D0 (en) Peptide imaging agents
WO2011015602A3 (en) Lung cancer biomarkers
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
MX2012014739A (es) Novedoso anticuerpo para el diagnostico y/o pronostico de cancer.
MX2012002139A (es) Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.
WO2008104803A3 (en) Proteins
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EA201791876A1 (ru) Моноклональные антитела к прогастрину и их применение
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2005111211A3 (en) Micronas and uses thereof
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2009126306A3 (en) Compositions and methods for detecting egfr mutations in cancer
WO2011041336A3 (en) Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
WO2013081645A3 (en) Erbb3 mutations in cancer